Author

Ricky M. Trigg

University of CambridgeORCID 0000-0001-9329-9344Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Bengt HallbergiD· 1 shared Charlotte Barrett· 1 shared Christopher Steel· 1 shared Emily R. JamesiD· 1 shared G. A. Amos BurkeiD· 1 shared Jamie D. MatthewsiD· 1 shared Leila Jahangiri· 1 shared Lucy HareiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bengt HallbergORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintSep 5, 2024

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma

Perla Pucci, Charlotte Barrett, Ricky M. Trigg…·Suzanne Dawn Turner

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

1 citation

humangenetic perturbation / CRISPR

𝕏 PostBluesky